-
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
15 Nov 2024 12:30 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)
13 Nov 2024 12:18 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)
13 Nov 2024 12:00 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Presents at National Brain Tumor Society’s Research Round Table
25 Jul 2023 11:26 GMT
… the Brain Cancer Research Roundtable organized by the National Brain Tumor Society … organized by the National Brain Tumor Society (NBTS). The event … 2, IL-4 and IL-13 Superkines and first in … Our focus on defeating brain tumors and improving the quality …
-
Medicenna Presents at National Brain Tumor Society's Research Round Table
25 Jul 2023 11:00 GMT
… the Brain Cancer Research Roundtable organized by the National Brain Tumor Society … organized by the National Brain Tumor Society (NBTS). The event … 2, IL-4 and IL-13 Superkines and first in … Our focus on defeating brain tumors and improving the quality …
-
Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (pembrolizumab) at the 39th Annual Meeting of SITC
11 Nov 2024 12:00 GMT
… IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
08 Nov 2024 15:07 GMT
… both our IL-2 and IL-13 Superkine platforms in one molecule … Company’s IL-2 and IL-13 Superkine Platforms, the former being … IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
08 Nov 2024 15:00 GMT
… both our IL-2 and IL-13 Superkine platforms in one molecule … Company’s IL-2 and IL-13 Superkine Platforms, the former being … IL-2, IL-4 and IL-13 Superkines and first-in-class … and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and …
-
Clinical trial approved by FDA for glioblastoma brain cancer
16 Mar 2022 01:45 GMT
… recurrent glioblastoma, a type of brain cancer. The phase I trial is … of the IL-4 and IL-13 cytokine receptor complex. This therapeutic …
-
Medicenna Presents Preclinical IL-13 Superkine Data at the AACR Annual Meeting
17 Apr 2023 11:00 GMT
… characterizing the Interleukin 13 (IL-13) Superkines, MDNA132 and … ability of our IL-13 Superkines to preferentially … Characterization of MDNA132, an IL-13 Decoy Receptor Selective Superkine … uniformly fatal form of brain cancer. Bizaxofusp has obtained …
About
© 1995-2024